Fruquintinib for previously treated metastatic colorectal cancer

Published on 04 Jun 2025
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended fruquintinib for inclusion on the MOH List of Subsidised Drugs for treating patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF agent, and if RAS wild-type, an anti-EGFR agent. The decision was due to the unfavourable cost effectiveness of fruquintinib compared with subsidised alternative treatment, based on the price proposal from the company.

Clinical indication, subsidy class and MediShield Life claim limit for fruquintinib are provided in the Annex.

Fruquintinib for previously treated metastatic colorectal cancer (Published 4 Jun 2025)